Shots:
- Recordati has received a non-binding indication of interest from CVC Capital Partners for a voluntary tender offer to acquire all outstanding shares & delist the company, subject to due diligence, financing, & partner identification
- Recordati expanded into rare diseases with its 2021 acquisition of EUSA Pharma for ~$845M, strengthening its rare cancer portfolio
- The proposal values Recordati at €52/share (cum dividend), implying a total equity value of ~€10.9B (~$12.6B); CVC, which already holds ~47% stake, aims to take the company private, although the offer has not yet been reviewed by Recordati’s corporate bodies
Ref: Recordati | Image: Recordati | Press Release
Related News: Recordati and Moderna Collaborate To Develop And Commercialize mRNA 3927 in a ~$160M Deal
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
